3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Active not recruiting
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Colorectal Neoplasms
27
Neoplasm Metastasis
5
Advanced Solid Tumors
5
Stomach Neoplasms
3
Parkinson Disease 4, Autosomal Dominant Lewy Body
3
Neoplasms
2
Colonic Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Advanced Solid Tumors (Excluding Breast Cancer)
2
Urologic Diseases
1
Spinocerebellar Degenerations
1
Solid Tumor Cancer
1
Small Cell Lung Carcinoma
1
Sarcoma, Ewing
1
Sarcoma, Alveolar Soft Part
1
Sarcoma
1
Renal Insufficiency
1
Refractory Solid Tumors
1
Rectal Neoplasms
1
Prostatic Neoplasms
1
Lung Neoplasms
1
Liver Neoplasms
1
Liver Diseases
1
Kidney Neoplasms
1
Kidney Diseases
1
Head and Neck Neoplasms
1
HER2 IHC3+ Advanced Colorectal Cancer
1
Esophageal Neoplasms
1
Endometrial Neoplasms
1
Desmoid Tumors
1
Interventions
Fluorouracil
12
pembrolizumab
9
Oxaliplatin
9
Nivolumab
9
Leucovorin
8
Capecitabine
7
Cisplatin
6
Trastuzumab
4
Paclitaxel
3
Drug Therapy
3
Docetaxel
3
zimberelimab
2
zanidatamab
2
tucatinib
2
spartalizumab
2
durvalumab
2
Radiotherapy
2
Levoleucovorin
2
Irinotecan
2
Gemcitabine
2
Carboplatin
2
130-nm albumin-bound paclitaxel
2
zolbetuximab
1
trifluridine tipiracil drug combination
1
trastuzumab deruxtecan
1
toripalimab
1
tislelizumab
1
tezacitabine
1
ribociclib
1
quemliclustat
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Adenocarcinoma Of Esophagus
×
trifluridine tipiracil drug combination
×
Clear all
NCT06356311
2026-02-27
TroFuse-015
Merck Sharp & Dohme LLC
Phase 3
Active not recruiting
450 enrolled